An interventional study of 3T-MRI scan in Unruptured Intracranial Aneurysm and Aneurysmal Subarachnoid Hemorrhage (aSAH), sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Subarachnoid Hemorrhage with a site in Switzerland — 4 open to participants now, 4 under way, none of them phase 3. Subarachnoid Hemorrhage · Switzerland.
Among the 24 studies in Subarachnoid Hemorrhage with a site in Switzerland, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2023, is one of 10 with no phase, and was the 24th registered.
511 studies on the registry are indexed under Subarachnoid Hemorrhage; 128 are open to participants now.
Browse Subarachnoid Hemorrhage studies →4 of the 24 studies in Subarachnoid Hemorrhage with a site in Switzerland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 16+
University Hospital, Geneva · Sites in Switzerland
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 89 Subarachnoid Hemorrhage studies recruiting now, 56 (63%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 30 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 57 across 264 interventional studies indexed under Subarachnoid Hemorrhage.
Median enrollment 90 across the 15 interventional studies, 198 across the 9 observational. Of the 19 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 24 have an industry lead sponsor. The 10 most frequent:
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 742 studies on the registry; 180 are open to participants now.
Insel Gruppe AG, University Hospital Bern has 7 studies filed under Subarachnoid Hemorrhage — fewer than ten, so there is no comparison to draw.
2 of the studies in Subarachnoid Hemorrhage with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04043598Insel Gruppe AG, University Hospital BernCrystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage | 2027-07 |
| NCT07938775Insel Gruppe AG, University Hospital BernSwiss Pilot Screening Study for Unruptured Intracranial Aneurysms to Prevent Subarachnoid Hemorrhage in Smokers | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Subarachnoid Hemorrhage with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Unruptured intracranial aneurysms (UIAs) are potentially life-threatening vascular lesions that may rupture and cause aneurysmal subarachnoid hemorrhage (SAH), a condition associated with substantial morbidity and mortality. The prevalence of UIAs in the general population is approximately 3.2%. Current guidelines recommend screening primarily for individuals with a strong family history of UIA/SAH or autosomal dominant polycystic kidney disease (ADPKD). However, these groups account for only a minority of patients with UIAs.
Smoking is a major modifiable risk factor for UIA formation and rupture. Preliminary studies suggest that UIA prevalence may be substantially higher among smokers than in the general population, but prospective data are limited, particularly in men.
This prospective screening study aims to determine the prevalence of UIAs in active and recent smokers aged 30-60 years with a smoking history of at least 10 pack-years. We hypothesize that UIA prevalence in this population is significantly higher than in the general population and may approach that of established high-risk groups.
Participants will undergo non-contrast 3T magnetic resonance angiography (time-of-flight sequence). Baseline demographic and clinical characteristics, smoking habits, nicotine dependence, and quality of life will be assessed using REDCap questionnaires. Imaging findings will be communicated to participants, and those with detected aneurysms or relevant incidental findings will be referred for standard clinical evaluation. At 30 (±14) days after MRI, smoking habits, nicotine dependence, quality of life, and consequences of screening will be reassessed. The study will also evaluate the clinical implications and costs of screening.
Unruptured intracranial aneurysms (UIA) are an asymptomatic but potentially life-threatening cardiovascular condition. Rupture leads to aneurysmal subarachnoid hemorrhage (SAH), which is associated with high morbidity and mortality and causes 25% of all cerebrovascular-related deaths. In Switzerland, approximately 275'000 people harbor an UIA. Screening with imaging for detection of UIA to occlude them preventively and thus reduce SAH incidence is recommended according to current guidelines only in patients with ≥2 family members with a history of UIA/SAH or who suffer from autosomal dominant polycystic kidney disease (ADPKD). In these two groups, considered to be at high risk of having UIA, the prevalence of UIA is estimated to be 10%, compared with an approximate prevalence of 3.2% in the general population. However, patients with a positive family history for ≥2 family members or ADPKD represent an absolute minority of all UIA patients.
In contrast, smoking is common in SAH patients and is the most substantial risk factor for SAH. Approximately 40% of patients presenting with SAH are active smokers, and 39% of smokers with UIA will experience SAH during their lifetime. There are few but interesting data on the prevalence of UIA in middle-aged women who are smokers, as the incidence of SAH is highest in this subgroup. A retrospective nested case-control study in 30 to 60-year-old women who underwent head MRI for various indications found an UIA prevalence of 19% in female smokers compared to a prevalence of 1.9% in non-smoking females. Further, a recent small screening study found an UIA prevalence of 12% (5 out of 43) in female smokers.
Switzerland has implemented several tobacco control measures over the past 25 years, and tobacco use declined moderately until 2007. Since then, smoking prevalence has stabilized but remains relevantly high at approximately one-quarter of the population. 27% of the Swiss population (15 years and older) are active smokers, and 22% are former smokers. Smoking 20 or more cigarettes a day is considered heavy smoking, is prevalent in 6% of the population and is more common in men (8% men, 4% women). Although previous studies screened women exclusively, smoking is the most critical risk factor for SAH in both sexes, and Swiss men are more frequently heavy smokers than women.
Smoking cessation leads to a decrease in SAH incidence and is, contrary to ADPKD and positive family history of SAH/UIA, a risk factor that can be targeted with lifestyle modifications to prevent future SAH. These data and the continuing relevant health burden caused by smoking challenge the current screening approach towards a risk factor-based UIA screening strategy targeting smoking patients. To investigate the value of such risk factor-based screening, more extensive data on UIA prevalence in smokers is needed, particularly in men, because they are missing.
We hypothesize that the prevalence of UIA in active smokers is relevantly higher than the average UIA-prevalence of 3.2% and comparable to other high-risk groups (≥2 family members with a history of SAH/UIA, ADPKD) in whom guidelines currently recommend screening. Further, we hypothesize that in a relevant proportion of UIAs that could potentially be detected by such screening, the risk of natural history is higher than the risk of treatment resulting in a recommendation to perform preventive aneurysm occlusion or to undergo lifestyle modifications and follow-up with imaging.
After obtaining the signed informed consent and inclusion in the study, demographics, risk factors for SAH / UIA, QoL (15-D questionnaire), and nicotine dependence, will be assessed in an online questionnaire and with help of an online survey tool (REDCap). The 3T-MRI examination will be scheduled as a next step, and the appointment will be communicated to the participant. The 3T-MRI exams will take place at the Translational Imaging Senter in Sitem-insel. As MRI machine we will use a 3 T scanner (MAGNETOM Prisma, Siemens Healthcare) with a standard head coil. The time for acquiring the necessary TOF-angiography sequence is approximately 5 minutes. After the examination, participants can go directly home and no further examinations will be performed at this appointment. Within seven days after the examination, participants will be contacted by the study team via telephone and findings of the examination will be communicated. If a UIA or an incidental finding is detected, the patients will be called to a consultation in the outpatient clinic outside of the study and will be managed based on the finding with standard care. 30 (±14) days after the MRI examination, QoL, changes in smoking habits, and nicotine dependence will again be collected via an online questionnaire and with help of an online survey tool (REDCap). Furthermore, planned or completed interventions and consequences of the screening findings will be collected, as well as costs of screening and potential interventions will be recorded.
The maximum duration of the study after the MRI examination is 30 (±14) days. Depending on the availability of MRI slots, the period between inclusion and MRI examination may vary but should not exceed 8 (±4) weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3T-MRI examination for Unruptured intracranial aneurysms
Device: 3T-MRI scan
After obtaining the signed informed consent, demographics, risk factors for SAH / UIA, QoL (15-D questionnaire), and nicotine dependence, will be assessed in an online questionnaire. The 3T-MRI examination will be performed. The time for acquiring the necessary TOF-angiography sequence is approximately 5 minutes. Within seven days after the examination, participants will be contacted by the study team via telephone and findings of the examination will be communicated. If a UIA or an incidental finding is detected, the patients will be called to a consultation in the outpatient clinic outside of the study and will be managed based on the finding with standard care. 30 (±14) days after the MRI examination, QoL, changes in smoking habits, and nicotine dependence will again be collected via an online questionnaire. Furthermore, planned or completed interinterventions and consequences of the screening findings will be collected.
percentage of Unruptured intracranial aneurysms detected by screening
Diagnostic yield calculated as the percentage of UIAs detected by screening
Time frame: 30 days after MRI
Kind of interventions for detected Unruptured intracranial aneurysms (none, observation/lifestyle modifications, preventive occlusion)
Interventions for detected Unruptured intracranial aneurysms (none, observation/lifestyle modifications, preventive occlusion)
Time frame: 30 days after MRI
Location of detected Unruptured intracranial aneurysms
Time frame: 7 days after MRI
Morphology of detected Unruptured intracranial aneurysms
Time frame: 7 days after MRI
Size of detected Unruptured intracranial aneurysms
Time frame: 7 days after MRI
Prevalence of incidental findings
Time frame: 7 days after MRI
Description of incidental MRI findings
Time frame: 7 days after Baseline MRI
Health Related Quality of Life (HRQoL) 15D
15D is a generic, comprehensive, 15-dimensional, standardized, self-administered measure of health-related quality of life (HRQoL). It includes the following 15 dimensions: breathing, mental function, speech (communication), vision, mobility, usual activities, vitality, hearing, eating, elimination, sleeping, distress, discomfort and symptoms, sexual activity, and depression. The maximum score is 1 (no problems on any dimension) and the minimum score is 0. A change of 0.02-0.03 has been observed to be such that people can feel the difference.
Time frame: at Baseline and 30 days after Baseline MRI
Effect of smoking dependency/smoking habits
Time frame: assessed before and after MRI
Costs of screening
Costs of screening compared to costs of SAH
Time frame: day 7 after MRI
Costs of potential interventions
Costs of potential interventions (including incidental findings) compared to costs of SAH
Time frame: day 7 after MRI
UIA detection rate with software
Time frame: day 7 after MRI
Prevalence ouf detected UIAs stratified by sex
Time frame: day 7 after MRI
Prevalence ouf detected UIAs stratified by pack-years
Time frame: day 7 after MRI
Prevalence ouf detected UIAs stratified by age
Time frame: day 7 after MRI
Started Jul 2023 (actual). Primary completion is estimated for Jul 2027, 48 months after the start.
Of 57 non-industry interventional studies with no phase under Subarachnoid Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 62. This study's planned 48 months is above that.
Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 20 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →